Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.
In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.
The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.
- Headquartered in Madison, Wisconsin
- Specializes in cancer screening and diagnostic tests
- Flagship product: Cologuard, a noninvasive colorectal cancer screening test
- Precision oncology products: Oncotype DX and OncoExTra
- Active development of liquid biopsy tests
- Exclusive intellectual property rights protecting screening technology
For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.
Exact Sciences Corp. (NASDAQ: EXAS) announced significant findings from the RxPONDER trial, presented at the 2020 San Antonio Breast Cancer Symposium, indicating that the Oncotype DX test can help avoid unnecessary chemotherapy for the majority of postmenopausal women with node-positive early-stage breast cancer. The study involved over 5,000 participants, revealing that two-thirds of postmenopausal women showed no chemotherapy benefit, while premenopausal women had a minor benefit. This research aims to refine treatment decisions and could impact tens of thousands of women globally.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in the Evercore ISI HealthCONx Conference on December 2, 2020, at 1:00 p.m. EST.
Investors can access the webcast through the investor relations section of the company's website.
Exact Sciences focuses on cancer screening and diagnostics, investing in its product pipeline to address various cancers and improve patient care.
For more details, visit exactsciences.com.
Exact Sciences Corp. (Nasdaq: EXAS) announced participation in two investor conferences in November 2020. These include a fireside chat at the Stifel Virtual Healthcare Conference on November 16 at 9:20 a.m. EST, and a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18 at 2:55 p.m. EST. Investors can access the webcasts via the company's website. The company specializes in cancer screening and diagnostic tests, including Cologuard and Oncotype DX, and is focused on expanding its product pipeline.
The United States Preventive Services Task Force (USPSTF) has drafted updated guidelines recommending colorectal cancer screening starting at age 45. Exact Sciences' Cologuard® is specifically included as a screening method for average-risk adults aged 45 to 75. Cologuard has demonstrated a 92% detection rate for colorectal cancers in a study involving nearly 10,000 patients. The guidelines aim to increase screening rates among 44 million unscreened Americans, highlighting a growing incidence of colorectal cancer in individuals under 50. A final recommendation is expected in 2021.
Exact Sciences Corporation (Nasdaq: EXAS) announced a registered direct offering of 8,605,483 shares at $101.00 per share, generating approximately $869.2 million in gross proceeds. The company plans to utilize the net proceeds of about $866.0 million for general corporate purposes, including debt repayment and the acquisition of Thrive Earlier Detection Corp.. The offering will close on or about October 29, 2020.
Exact Sciences Corp. (Nasdaq: EXAS) reported third-quarter revenue of $408.4 million for the period ending September 30, 2020, up from $218.8 million in 2019. Despite a 2% decrease in screening revenue at $214.6 million, they achieved $102.2 million from COVID-19 testing. The company faced a net loss of $219.9 million or $1.46 per share, a significant increase from the previous year. Gross margin was 72%, while adjusted EBITDA was $94.5 million. The company retained $1.3 billion in cash and equivalents, indicating robust liquidity.
Exact Sciences Corp. (Nasdaq: EXAS) announced its agreement to acquire Thrive Earlier Detection Corp. for up to $2.15 billion in cash and stock. This transaction, approved by both companies' boards, is expected to close in Q1 2021, pending regulatory approvals. The acquisition aims to combine Thrive's CancerSEEK test with Exact Sciences' platform, enhancing blood-based multi-cancer screening capabilities. The merger is projected to strengthen Exact Sciences' position in the growing cancer diagnostics market, estimated at over $25 billion.
Exact Sciences Corp. (NASDAQ: EXAS) announced the launch of the Oncotype MAP™ Pan-Cancer Tissue test, aimed at patients with advanced, metastatic, refractory, or recurrent cancer. This test offers actionable insights from genomic alterations in hundreds of cancer-related genes, enabling tailored therapy recommendations. Key features include a rapid turnaround time of 3-5 business days, minimal tissue requirements, and a significant increase in progression-free survival rates. The test is available for physicians in the U.S. and is covered by Medicare for qualifying patients.
Exact Sciences Corp. (Nasdaq: EXAS) will release its third quarter 2020 financial results on October 29, 2020, after market close. A conference call will follow at 5 p.m. ET to discuss the results and business updates. The company continues to focus on cancer screening and diagnostic solutions, building on its Cologuard and Oncotype DX success. The press release also indicates that forward-looking statements regarding future results are subject to risks, including impacts from the COVID-19 pandemic on operations and product demand.
On September 17, 2020, Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in the Cowen Liquid Biopsy Summit on September 24, 2020, at 10:30 a.m. EDT. Investors can access the event via a webcast on the company's investor relations page. Known for its innovative cancer screening solutions like Cologuard and Oncotype DX, Exact Sciences is committed to advancing diagnostic technologies. The company faces uncertainties related to the COVID-19 pandemic but continues to invest in improving patient care and expanding its product pipeline.
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
What is Exact Sciences Corp's main business?
What is Cologuard?
Where is Exact Sciences Corp headquartered?
What are Oncotype DX and OncoExTra?
Is Exact Sciences developing any new tests?
What is the significance of Exact Sciences' intellectual property?
Are Exact Sciences' products used internationally?
How does Cologuard work?
What is the purpose of Oncotype DX tests?
Where can more information about Cologuard be found?
